| May 9, 2024 | Aardvark | $85.0M Series C | Victor Tong | Cantor Fitzgerald, Cormorant Asset Management, Theresa Strong, LG Technology Ventures, Silver Arc Private Capital, Surveyor Capital, SymBiosis, Tetragon Financial Group, Stacy Ward, Vickers Venture Partners, Walleye Capital |
| Aug 17, 2023 | COMPASS Pathways | $285.1M Other Equity | Aisling Capital, TCGX | Armistice Capital, Logos Capital, Paradigm BioCapital, PFM Health Sciences, RA Capital Management, Soleus Capital, Surveyor Capital, Vivo Capital |
| Jul 1, 2023 | MerQube | $22.0M Series B | Intel Capital | F-Prime Capital Partners, Nyca Partners, Allianz Life Ventures, Citi, J.P. Morgan, UBS |
| Apr 26, 2023 | Axoni | $20.0M Other Equity | Jonathan Bresler | Andreessen Horowitz, Citi, CME Ventures, Coatue, Communitas Capital, Data Collective, Deutsche Bank, Digital Currency Group, FinTech Collective, F-Prime Capital, Franklin Templeton, Goldman Sachs, HSBC, Intel Capital, J.P. Morgan, Emmanuel Naim, London Stock Exchange Group, Nyca Partners, UBS, Wells Fargo, Y Combinator |
| Dec 16, 2022 | Opensee | $11.7M Series A | Omnes Capital | SG |
| Sep 1, 2022 | RayzeBio | $160.0M Series D | Sofinnova Investments, Viking Global Investors, Irina Margine, Ph.D. | Cambridge Innovation Capital, Forbion, Ally Bridge Group, Sands Capital, Soleus Capital |
| Mar 1, 2022 | TRex Bio | $26.0M Series A | Alexandra Cantley | Polaris Partners, Alexandria Venture Investments, Eli Lilly and Company, Johnson & Johnson Innovation, Alexander Duncan, Ph.D., SV Health Investors |
| Feb 24, 2022 | Scipher Medicine | $110.0M Other Equity | Tim Anderson | Alumni Ventures, Echo Health Ventures, Hitachi Ventures, Khosla Ventures, Monashee Investment Management, Neuberger Berman, Michael Rubin, Optum Ventures |
| Dec 14, 2021 | AnHeart Therapeutics | $61.0M Series B | Ting Jia (TJ) | Cenova Capital, Innovent Biologics, Sage Partners |
| Dec 1, 2021 | Ambys Medicines | $47.0M Series A | Third Rock Ventures | ARCH Venture Partners, Frazier Healthcare Partners, Matrix Capital Management Company, SignalFire, Alexandria Venture Investments, Erwin Boos, Smilegate Investment, Takeda |
| Sep 1, 2021 | LEXEO Therapeutics | $100.0M Series B | Daniel Saul Sundheim, Joy Ghosh | Omega Funds, Alexandria Venture Investments, CAM Capital, Gray's Creek Capital Partners, Invus, Janus Henderson Investors, Longitude Capital, Lundbeckfond Ventures, PBM Capital, Verition Fund Management, Woodline Partners |
| Aug 5, 2021 | Pepgen | $112.5M Other Equity | — | Adage Capital Management, CureDuchenne Ventures, Deerfield Management, Gray's Creek Capital Partners, Alexis Dormandy, Joshua Resnick, Samsara BioCapital, Tudor Ventures, Viking Global Investors |
| Apr 27, 2021 | Exscientia | $225.0M Series D | SoftBank Vision Fund 2 | BlackRock, Bristol Myers Squibb, Casdin Capital, Andrew Hopkins, Farallon Capital Management, GT Healthcare Capital Partners, Hongkou, Marshall Wace, Novo Holdings, Pivotal bioVenture Partners |
| Mar 1, 2021 | Pyxis Oncology | $150.0M Series B | Christian Schetter, gotham makker | Pfizer Venture Investments, Acuta Capital Partners, Agent Capital, BVF Partners, Cormorant Asset Management, HBM Healthcare Investments, Janus Henderson Investors, Leaps by Bayer, LifeSci Venture Partners, Logos Capital, Longwood Fund, Perceptive Advisors, RA Capital Management, Ridgeback Capital Investments, Surveyor Capital, Tekla Capital Management |
| Sep 10, 2020 | Recursion | $239.0M Series D | Juergen Eckhardt | Advantage Capital, Casdin Capital, Catalio Capital Management, Data Collective, Epic Ventures, Felicis Ventures, Intermountain Ventures, Lux Capital, Obvious Ventures, Samsara BioCapital, Two Sigma Ventures |
| Sep 1, 2020 | Recursion Pharmaceuticals | $240.0M Series D | Juergen Eckhardt | 01 Advisors, Album VC, Dimension Capital, Advantage Capital, Casdin Capital, Catalio Capital Management, Epic Ventures, Felicis Ventures, Intermountain Ventures, Lux Capital, Obvious Ventures, Samsara BioCapital, Two Sigma Ventures |
| Apr 1, 2019 | SpringWorks Therapeutics | $125.0M Series B | Adam Stone | ArrowMark Partners, Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, LifeArc, OrbiMed, Pfizer, Samsara BioCapital, Surveyor Capital |
